Search results
Results from the WOW.Com Content Network
Gigantism (Greek: γίγας, gígas, "giant", plural γίγαντες, gígantes), also known as giantism, is a condition characterized by excessive growth and height significantly above average. In humans, this condition is caused by over-production of growth hormone in childhood.
The long-acting forms of these drugs must be injected every 2 to 4 weeks for effective treatment. Most people with acromegaly respond to this medication. In many people with acromegaly, GH levels fall within one hour and headaches improve within minutes after the injection. Octreotide and lanreotide are effective for long-term treatment.
GH treatment usually decreases insulin sensitivity, [24] but some studies showed no evidence for increased diabetes incidence in GH-treated adult hypopituitary patients. [ 25 ] In past it was believed that GH treatment could increase the cancer risk; a large study recently concluded that "With relatively short follow-up, the overall primary ...
Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones; [3] [medical citation needed] it typically results from a pituitary adenoma.In children with hyperpituitarism, disruption of growth regulation is rare, either because of hormone hypersecretion or because of manifestations caused by local compression of the adenoma.
Local gigantism affecting second toe of a child Local gigantism or localised gigantism is a condition in which a certain part of the body acquires larger than normal size due to excessive growth of the anatomical structures or abnormal accumulation of substances.
Bahasa Indonesia; Português; Simple English; Slovenščina; ... People with gigantism (2 C, 93 P) P. People with acromegaly (1 C, 25 P) S. Syndromes affecting ...
Growth hormone deficiency in childhood commonly has no identifiable cause (idiopathic), and adult-onset GHD is commonly due to pituitary tumours and their treatment or to cranial irradiation. [9] A more complete list of causes includes:
Low IGF-1 levels are shown to increase the risk of developing type 2 diabetes and insulin resistance. [67] On the other hand, a high IGF-1 bioavailability in people with diabetes may delay or prevent diabetes-associated complications, as it improves impaired small blood vessel function. [67] IGF-1 has been characterized as an insulin sensitizer ...